On air · 1 of 3 networks
Altus Biologics
- altusbiologics.com
- Healthcare & Life Sciences
- US
- 128 employees
Altus Biologics’s ads on LinkedIn, Meta and Google, recorded by adsrunning. Browse the latest here for free. Sign up free to see all 20. Watch Altus Biologics with Starter to get each new one in your feed.
Watchlist with Starter · $49/mo
| Network | Status | Live ads | Nov 2025LinkedIn activity · 52 weeksOct 2026 | Checked | Next step |
|---|---|---|---|---|---|
| Running | 20 | Checked 30 Oct 2026 | See all 20 ads → | ||
| Meta | None recorded | 0 | No active ads recorded on the Meta Ad Library | Checked 17 Oct 2026 | Collect them with the API → |
| None recorded | 0 | No ads found on the Google Ads Transparency Center | Checked 2 Oct 2026 | Collect them with the API → |
Altus Biologics has 20 live LinkedIn ads. Its Facebook page had no active ads on 17 Oct 2026, and we recorded no Google ads on 2 Oct 2026.
Latest ads
- LINKEDIN · IMAGERecorded 4 Sept 2026
Biologic therapies have transformed 🔀 the care landscape for patients living with moderate-to-severe asthma and allergic diseases. Yet, success depends on more than prescribing the appropriate medication; it requires a coordinated, patient-centered program that blends clinical precision with ☑️ operational excellence.
- LINKEDIN · IMAGERecorded 4 Sept 2026
For specialty practices, expanding treatment 💊 options with an in-office infusion suite is more than a convenience; it’s a strategy to strengthen patient outcomes and operational efficiency.
- LINKEDIN · IMAGERecorded 4 Sept 2026
For specialty practices delivering in-office 🧪 biologic therapy, protecting patient access isn’t just about clinical excellence; it’s about navigating an increasingly complex insurance landscape. One of the fastest-growing 📈 threats to stable patient care is the rise of Alternative Funding Programs.
- LINKEDIN · IMAGERecorded 4 Sept 2026
The 340B Drug Pricing Program has long served as a critical lifeline for safety-net hospitals and health systems, but today is under threat. For specialty providers, the implications of this shift reach far beyond policy; they strike at the heart of patient access, practice finances, and the sustainability of care for underserved communities.
- LINKEDIN · IMAGERecorded 4 Sept 2026
Delays in patient access to 🧪 biologic therapies remain one of the most pressing challenges across healthcare specialties. Prior authorizations, step therapy barriers, and complex payer requirements can transform what should be a straightforward treatment plan into a frustrating waiting game. At Altus Biologics, we’ve built our model to help you relieve 🔀 these bottlenecks, streamline workflows, and accelerate patient access to biologic therapies.
- LINKEDIN · IMAGERecorded 4 Sept 2026
A quiet but significant 🔁 change is coming to the 340B Program, and it could reshape the way your practice manages high-cost specialty drugs. Starting in 2026, the Department of Health and Human Services (HHS) will test a new Rebate Model Pilot that lets drug manufacturers offer rebates instead of the traditional upfront discounts on certain 340B drugs. In our latest blog, we explore what’s changing, why it matters, and how you can ✅ prepare.
6 of 20 adsSign up to see every Altus Biologics ad, filter by format and date, and get alerts on new ones.
See all 20 adsWatch the companies you care about.
Filter every ad by industry, country, format and network, and get alerts when a company you watch starts running new ads.